Journal profile · Hematology
Hematological Oncology
ISSN 0278-0232 · eISSN 1099-1069 · John Wiley and Sons Ltd · ENGLAND · Quarterly · Founded 1983
Hematological Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.09; hybrid open access; APC about USD 4,650; median 102 days to acceptance (40 articles, last 24 months); community-reported acceptance: fairly easy; 1,063 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Hematological Oncology is published by John Wiley and Sons Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and CAR-T cell therapy research, together about 51.4% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders Diagnostic investigations, including imaging and laboratory assays Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance. We work together with Wiley’s open access journal, Clinical Case Reports, to enable rapid publication of good quality case reports that we are unable to accept for publication in our journal. Authors of case reports rejected by our journal will be offered the option of having their case report, along with any related peer reviews, automatically transferred for consideration by the ClClinical Case Reports editorial team. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. Clinical Case Reports will consider case reports from every clinical discipline and may include clinical images or clinical videos. Clinical Case Reports is an open access journal, and article publication fees apply. For more information please go to www.clinicalcasesjournal.com.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Li Chai BrighamPublisher website
Editorial board by country: 2 in mainland China (about 9%); most named Italy 5, United States 4, Germany 3, Switzerland 3, Mainland China 2 (23 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine28.3%
- Chronic Lymphocytic Leukemia ResearchMedicine15.1%
- CAR-T cell therapy researchMedicine8%
- CNS Lymphoma Diagnosis and TreatmentMedicine5%
- Viral-associated cancers and disordersMedicine4.9%
- Acute Myeloid Leukemia ResearchMedicine4.2%
- Acute Lymphoblastic Leukemia researchMedicine4.1%
- Lung Cancer Treatments and MutationsMedicine2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.09LetPub ·
- Impact factor (publisher)
- 4.1Publisher website ·
- Impact factor (publisher) 2025
- 4.1Publisher website ·
- CiteScore 2026-06
- 5.2LetPub ·
- CiteScore (publisher)
- 5.2Publisher website ·
- CiteScore (publisher) 2025
- 5.2Publisher website ·
- SJR 2026-06
- 1.07LetPub ·
- SNIP 2026-06
- 0.9LetPub ·
- h-index
- 42LetPub ·
- h-index
- 74OpenAlex ·
- i10-index
- 1,156OpenAlex ·
- 2-year mean citedness
- 0.65OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 49%LetPub ·
Volume
- Articles per year
- 95LetPub ·
- Articles per year (publisher) 2025
- 100Publisher website ·
- Downloads per year (publisher) 2025
- 592,583Publisher website ·
Articles by year OpenAlex count · 6,054 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 107 | 68 | 17 |
| 2025 | 1,063 | 1,014 | 482 |
| 2024 | 106 | 68 | 327 |
| 2023 | 836 | 796 | 1,757 |
| 2022 | 167 | 75 | 1,401 |
| 2021 | 531 | 365 | 2,045 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
102 daysMedian, submission to acceptance · P25–P75 62 days – 147 days
- Acceptance to online
- median 10 days (41 articles)
- Submission to online
- median 115 days
- Sample
- 40 articles with submission and acceptance dates (1,172 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 12%Publisher website ·
- Acceptance rate (publisher) 2025
- 12%Publisher website ·
- Submission to first decision
- 13 daysPublisher website ·
- Submission to first decision 2025
- 13 daysPublisher website ·
- Submission to acceptance 2025
- 97 daysPublisher website ·
- Acceptance to publication 2025
- 12 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,650 / EUR 3,920 / GBP 3,120 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- First submission
- Free format: the journal's layout is not required
- Cover letter
- Required
Article types accepted6
- case reportArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
- commentaryArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
- letter to the editorArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
- original articleArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
- perspectiveArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
- reviewArticle Type Description Word Limit (excluding cover page, abstract, references, tables, and figures) Max number of figures and tables sakk.oncoviews.com Abstra…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics 5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
Peer Review and AcceptanceThe acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are double-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determine that the paper meets the appropriate quality and relevance requirements.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 1983
- ISSN
- 0278-0232
- Electronic ISSN
- 1099-1069
- Latest issue on the website
- Volume 44, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Hematological Oncology
What CAS zone is Hematological Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hematological Oncology is in Zone 4 of Medicine, and in Zone 3 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hematological Oncology?
The latest impact factor listed by LetPub is 3.09; CiteScore 5.2, h-index 74.
How long does peer review take at Hematological Oncology?
Based on the dates recorded on 40 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 102 days (interquartile range 62–147 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 12% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Hematological Oncology?
According to the journal's author guidelines: First submission: Free format: the journal's layout is not required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Hematological Oncology based?
Of the 23 board members whose country the journal's board page names, 2 (about 9%) are in mainland China; the countries named most often are Italy (5), United States (4) and Germany (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Hematological Oncology?
According to LetPub and DOAJ records, Hematological Oncology is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Hematological Oncology open access, and what is the APC?
Hematological Oncology is a hybrid journal. For open-access publication: APC about USD 4,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .